Yoga in Improving Chronic Pain in Patients with Chemotherapy-Induced Peripheral Neuropathy
- Self-report >= 4/10 worst CIPN pain over the past week
- At least three months post neurotoxic chemotherapy completion
- Signed informed consent
- Willingness to participate in all study activities
- Speak/read English
- Prognosis of less than three months
- Documented peripheral neuropathy due to other causes (e.g., diabetes)
- Planned receipt of neurotoxic chemotherapy during the study period
- Practice yoga an average of > 45 minutes per week over the past six months
- Diagnosis or documented recent history of significant psychiatric comorbidity (i.e., psychosis, suicidal ideation, or substance abuse)
- Clinician deems that the patient is physically/functionally unable to participate in a yoga program
- Adults unable to consent
- Pregnant women
I a. Determine the feasibility of yoga implementation by calculating participant recruitment, retention, and adherence rates in both groups of a randomized eight-week yoga trial.
I b. Explore intervention group participants’ perspectives of acceptability and satisfaction with the eight-week yoga intervention using semi-structured telephone interviews.
II. Characterize changes within and between study groups over the eight-week intervention period with regard to worst chemotherapy-induced peripheral neuropathy (CIPN) pain intensity, CIPN severity, physical function, sleep-related impairment, anxiety, depression, and fatigue (SPADE symptoms), and salivary cortisol.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive therapist guided, in-person, group yoga for up to 2 classes weekly over 45 minutes each for 8 weeks.
GROUP II: Patients receive usual care and symptom management strategies from clinicians for 8 weeks. After completion of data collection in the 8-week study time frame, patients are encouraged to attend the yoga classes.
Trial Phase Phase NA
Trial Type Supportive care
Dana-Farber Harvard Cancer Center
Robert J Knoerl
- Primary ID 18-578
- Secondary IDs NCI-2019-01787
- Clinicaltrials.gov ID NCT03824860